New hippocampal neurons were found in people up to age 87, and neurologically healthy older adults had more abundant neurogenesis than people with Alzheimer’s disease. (Nature Medicine)
Eisai announced the start of a 1,566-patient phase III trial of the anti-amyloid agent BAN2401 to treat Alzheimer’s disease, the day after the company and its partner Biogen scrapped studies of aducanumab, another amyloid-targeting drug.
Should Wall Street ditch anti-amyloid drugs? Analysts say yes; scientists disagree. (MarketWatch)
A clinical review of gabapentinoid drugs — namely, gabapentin (Neurontin) and pregabalin (Lyrica) — showed limited evidence off-label for pain. (JAMA Internal Medicine)
Exposure to common pesticides in early life was linked to a small increased risk of autism spectrum disorder. (The BMJ)
A single most effective and safe treatment option for behavioral and psychological symptoms of dementia may not exist, a meta-analysis suggested. (JAMA Network Open)
Children with autism spectrum disorder (ASD) who used Superpower Glass, a wearable Google Glass-based intervention, showed significant improvement in socialization over ASD children who received standard-of-care behavioral therapy. (JAMA Pediatrics)
A nurse-led model increased quality of care for patients with Parkinson’s disease, a randomized trial showed. (Neurology)
Fentanyl deaths doubled every year from 2014 to 2016, according to the CDC. (National Vital Statistics Report)
Only a few days are left before the April 1 deadline to submit comments on a federal task force draft report on Pain Management Best Practices.
Did continuing medical education (CME) for breakthrough pain contribute to the opioid problem? (World Medical and Health Policy)